Psyence BioMed now has a contract manufacturer for ibogaine in the United States. On October 5, the company said its wholly owned subsidiary, Texas Ibogaine Research Corporation, had entered a manufacturing services agreement with Benuvia Operations of Round Rock, Texas, for the planned U.S. manufacture of pharmaceutical-grade ibogaine active pharmaceutical ingredient under cGMP standards.
It is the fourth announcement in three weeks, and together they describe a company assembling the parts of a U.S. ibogaine program in a deliberate order: a corporate vehicle, a supply source, exclusive rights, a manufacturer. What the sequence does not yet include is any authorization to produce the drug or to test it in people. With the manufacturer named, the constraint has moved to the Drug Enforcement Administration and the FDA, and the public record shows how much is still open there.
Three weeks, four steps
On September 14, Psyence announced the formation of Texas Ibogaine Research Corporation, or TIRC, as its U.S. vehicle for ibogaine development, to hold rights, manufacturing arrangements, and “any future investigational new drug application” in one entity.
On September 23, it announced an investment of up to $5 million in Psyence Labs, known as PsyLabs, the privately held company that is to supply the ibogaine. Of that, $2.4 million is committed; the remaining $2.6 million is a milestone-dependent backstop that lapses if not called and completed by December 31. Alongside it came a share exchange valued at about $9 million on each side. Before the transactions, PsyLabs held about 30.2 percent of Psyence and Psyence held about 29.2 percent of PsyLabs. After the share exchange and the committed investment, the company says, PsyLabs will hold about 49.9 percent of Psyence and Psyence about 41.1 percent of PsyLabs. The share exchange is subject to closing conditions and can be terminated by any party if it has not closed by November 30.
On September 25, TIRC and PsyLabs signed a binding term sheet, filed with the SEC in redacted form. It gives TIRC an exclusive U.S. license to PsyLabs’ know-how for its ibogaine hydrochloride, makes PsyLabs TIRC’s exclusive supplier, and appoints TIRC the exclusive U.S. wholesaler and distributor, for all indications. The filed copy redacts the payment terms. Psyence’s own description of them is that TIRC will pay development and regulatory milestones of up to about $1.3 million for a first drug candidate, a low single-digit royalty on net sales, and an annual exclusivity fee after a first FDA approval. The term sheet lapses automatically if a definitive agreement is not signed by November 30, unless both sides extend it. Psyence discloses that it is a related-party transaction and that members of its management are affiliates of PsyLabs with financial interests in it.
Then came Benuvia. Unlike the PsyLabs term sheet and the September investment agreements, the manufacturing services agreement was not filed with the SEC. The October 5 filing attaches only the press release, so the agreement’s term, exclusivity, volumes, and pricing are not public.
What the manufacturer adds
Benuvia is an established controlled-substance manufacturer. The release describes an 83,000-square-foot, DEA-registered facility, and the Federal Register shows the company has filed bulk-manufacturer and importer applications with the DEA repeatedly since 2020, across a widening list of Schedule I compounds. For a company with no U.S. manufacturing footprint, a contract with a facility already built for this work is a substantive step. TIRC’s project lead, Dr. John Thorne, described the purpose in regulatory terms: a U.S. manufacturing pathway is “intended to strengthen chain-of-custody controls, batch consistency and the chemistry, manufacturing and controls work required to support future regulatory submissions.”
That is a credible reason to sign a manufacturer early. Chemistry, manufacturing, and controls data are a required part of any investigational new drug application, and for a Schedule I substance the lead times run through the DEA.
What the DEA record shows
The press release says Benuvia is advancing applications for “the import permit and procurement quota required for the planned production.” The Federal Register shows where at least part of that stands. On August 11, Benuvia applied to be registered as an importer of ibogaine, and the DEA published notice of the application on September 28. The company’s stated purpose is to import ibogaine “to support internal research and development toward the bulk manufacture of API for future clinical trials,” and the notice adds that no other activity for the drug is authorized under the registration. Other registered manufacturers and applicants may file objections or request a hearing until October 28.
So when the Psyence agreement was announced, the import registration Benuvia needs for this purpose was a pending application in an open comment period. The application predates TIRC’s formation by a month, and neither company has said whether it is the one the press release refers to, though the purpose matches.
The import route matters because of how the supply is structured. Under the term sheet, TIRC must buy all of its ibogaine, natural or synthetic, exclusively from PsyLabs, and may not develop any product containing ibogaine sourced from a third party. PsyLabs is headquartered in the British Virgin Islands, according to Psyence’s annual report, and describes itself as licensed “in its operating jurisdiction” to cultivate, extract, and export. A U.S. program built on PsyLabs material therefore depends on importing a Schedule I substance. Federal law permits that only in narrow cases, and the DEA’s notice says permit applications will be approved only where the activity is consistent with them. The one that fits a development program allows import “in limited quantities exclusively for scientific, analytical, or research uses.” That can support research and clinical supply. It is not a route to commercial volumes.
The quota claim is harder to assess. Psyence’s release says that, “according to Benuvia,” the manufacturer “currently holds approximately half of the U.S. aggregate production quota for ibogaine,” and the release’s own disclaimer says information about Benuvia’s registration and quota allocations “has been provided by Benuvia and has not been independently verified by the Company.” The DEA does not publish individual manufacturers’ quotas, so the share cannot be checked from the public record. The total can. The established 2026 aggregate production quota for ibogaine, the most that all U.S. manufacturers combined may produce in the year, is 210 grams.
Half of that is about 105 grams. Benuvia’s chief executive, Terry Novak, framed scale the same way, saying the company can manufacture “at the scale this program will require if and as DEA quota expands.” Psyence states the dependency directly: because the facility exists, “the timing and scale of any U.S. ibogaine production will be governed primarily by applicable DEA quotas, controlled-substance import requirements and other regulatory authorizations.”
The release also leaves a question unanswered. A production quota governs how much ibogaine a registered bulk manufacturer may make in the United States. A procurement quota governs how much a manufacturer may obtain to turn into dosage forms or other substances. An import permit governs what may be brought in. Benuvia’s claimed share of the production quota and TIRC’s obligation to source exclusively from PsyLabs point at different activities, and the companies have not explained how the two fit together.
No trial, no application
The clinical program is less advanced than the infrastructure. On September 23 the company said it was “actively advancing plans for a potential ibogaine clinical trial in Texas” for opioid use disorder, and in the same release that it was “currently evaluating the feasibility and design” of such a trial, subject to protocol development, regulatory authorization, institutional approvals, funding, and site selection. The October 5 release is more explicit: “no trial has been commenced, and no regulatory application in respect of it has been filed or accepted.”
ClinicalTrials.gov lists no ibogaine study sponsored by Psyence or TIRC as of October 5. The one study the registry lists under the Psyence name is a psilocybin trial in Australia.
The Texas setting
Psyence has tied the program to Texas, saying the state “has emerged as an important state for publicly supported ibogaine research.” It has. Under Senate Bill 2308, which funds an ibogaine trial run by a public university in partnership with a drug company and a hospital, the Texas Health and Human Services Commission awarded $50 million in December 2025 to UTHealth Houston and UTMB Health to lead a two-year, multi-institution trial consortium, with a requirement for an equal amount of non-state matching funds. The universities’ announcement named no drug developer, manufacturer, or supplier.
The drug-company side of that design has not been filled. On March 31, the lieutenant governor and the House speaker said the commission had found that no drug company had yet submitted a proposal meeting the law’s requirements, and that Texas would conduct the research with its own institutions and intended to fully fund it.
Nothing in Psyence’s filings says TIRC has received a state award, joined that consortium, or holds any formal role in the Texas program. The company’s language is that a Texas presence “positions” it to participate. A Texas subsidiary and a Texas manufacturer are a location, not state backing.
What this changes for Psyence
Psyence calls itself vertically integrated and describes an “end-to-end pathway.” The structure is better described as contracted. Its supplier is an affiliate it will own about 41 percent of, under a term sheet that expires in eight weeks without a definitive agreement. Its manufacturer is a contractor whose agreement terms are undisclosed, and the company lists “reliance on a single manufacturing partner” among its risks. What TIRC would own outright, under the term sheet, is the downstream asset: drug candidate IP, clinical data, and regulatory filings.
The capital behind the plan is modest. Psyence reported a cash balance of $7.5 million at March 31, 2026, a net loss of $6.9 million for the fiscal year, and reliance on an equity line for liquidity, and its annual report says its ability to continue as a going concern depends on raising more. It has consolidated its shares twice since May 2025 to meet Nasdaq’s minimum bid price.
There is a fair case that none of this is premature. A sponsor cannot file an IND for a Schedule I drug without a characterized, lawfully sourced supply and a manufacturing plan, and the DEA steps are slow. Securing them before the protocol is finished is how controlled-substance development is normally sequenced. On that reading, Psyence has done the unglamorous work first.
The other reading is that the infrastructure is ahead of the program it is meant to serve. There is no IND, no protocol, no site, and no registered trial, and the FDA has not approved ibogaine for any use. Psyence’s own filings state that the drug’s safety and efficacy have not been established through authorized clinical research.
Both readings point to the same next evidence. Finding a manufacturer is no longer the open question. Whether that manufacturer is allowed to bring ibogaine in and make anything with it is.
The dates are close together. Objections to Benuvia’s import registration are due October 28. The PsyLabs term sheet and the share exchange both run to November 30. The DEA’s proposed 2027 production quotas, published in late November last year, will show whether the 210-gram ceiling moves. And the first sign of a clinical program would be the thing the company says does not yet exist: a filed application.